Search

Author/Creator Schwartz, G G

1. Efficacy and safety of inclisiran in patients with established cerebrovascular disease: pooled, post hoc analysis of the ORION-9, ORION-10 and ORION-11, phase 3 randomised clinical trials. (14th October 2021)

Authors:
Koenig, W; Ray, K K; Kallend, D G; Landmesser, U; Leiter, L A; Schwartz, G G; Wright, R S; Garcia Conde, L; Jaros, M; Raal, F J
Journal:
European heart journal
Issue:
Volume 42(2021)Supplement 1
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Efficacy and safety of inclisiran in patients with polyvascular disease: pooled, post hoc analysis of the ORION-9, ORION-10 and ORION-11, phase 3 randomised controlled trials. (14th October 2021)

Authors:
Koenig, W; Ray, K K; Kallend, D G; Landmesser, U; Leiter, L A; Schwartz, G G; Wright, R S; Garcia Conde, L; Jaros, M; Raal, F J
Journal:
European heart journal
Issue:
Volume 42(2021)Supplement 1
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Lipoprotein(a) and the effect of alirocumab on coronary and non-coronary revascularization following acute coronary syndrome. (3rd October 2022)

Authors:
Steg, P; Szarek, M; Valgimigli, M; Islam, S; Zeiher, A M; Bhatt, D L; Bittner, V A; Diaz, R; Goodman, S G; Harrington, R A; Jukema, J W; Pordy, R; Scemama, M; White, H D; Schwartz, G G
Journal:
European heart journal
Issue:
Volume 43(2022)Supplement 2
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Longer-term safety of alirocumab with 24, 610 patient-years of placebo-controlled observation: further insights from the ODYSSEY OUTCOMES trial. (3rd October 2022)

Authors:
Goodman, S; Steg, P G; Szarek, M; Bhatt, D L; Bittner, V A; Diaz, R; Harrington, R A; Jukema, J W; White, H D; Zeiher, A M; Manvelian, G; Poulouin, Y; Scemama, M; Stipek, W; Schwartz, G G
Journal:
European heart journal
Issue:
Volume 43(2022)Supplement 2
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Reduction in the risk of MACE with apabetalone in patients with recent acute coronary syndrome and diabetes according to NAFLD fibrosis score: exploratory analysis of the BETonMACE trial. (14th October 2021)

Authors:
Toth, P P; Schwartz, G G; Nicholls, S J; Halliday, C; Ginsberg, H N; Johansson, J O; Kalantar-Zadeh, K; Kulikowski, E; Lebioda, K; Wong, N; Sweeney, M; Ray, K K
Journal:
European heart journal
Issue:
Volume 42(2021)Supplement 1
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search